logo
Questions? +1 (202) 335-3939 Login
Set Up FREE Account Submit Release
Trusted News Since 1995
A service for pharmaceutical industry professionals · Sunday, June 22, 2025 · 824,487,399 Articles · 3+ Million Readers
Home  •••  Newswires by Industry  •  Countries  •  U.S. States  •  World Media Directory
Pharmaceutical Industry News  •••  Topics  •  Countries  •  U.S. States

Gilead Sciences News Monitoring

  • Published on Jun 19, 2025

    US approves Gilead’s twice-yearly injection to prevent HIV

    (FILES) The Gilead Sciences sign is seen outside their headquarters in Foster City, California on April 30, 2020. The US Food and Drug Administration on June 18, 2025 approved Gilead Sciences' twice-yearly injection to prevent HIV -- a move the company …

    Source: Jamaica Observer - Indeterminate
  • Published on Jun 19, 2025

    FDA approves twice-yearly shot for HIV prevention

    Add topic to email alerts Subscribe We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Back to Healio Key takeaways: Lenacapavir is the second long-acting …

    Source: Healio News - Neutral
  • Published on Jun 19, 2025

    FDA signs off on Gilead's landmark long-acting PrEP med, signaling new era in HIV prevention

    With the FDA’s much-anticipated nod for Gilead Sciences’ long-acting HIV pre-exposure prophylaxis (PrEP) injection Yeztugo (lenacapavir), a new era of HIV prevention has dawned. The approval, which came a day ahead of its June 19 scheduled FDA decision …

    Source: Fierce Pharma - Neutral
  • Published on Jun 19, 2025

    Trastuzumab deruxtecan plus pertuzumab ‘nearly doubles’ disease control in breast cancer

    Add topic to email alerts Subscribe We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Back to Healio Key takeaways: Trastuzumab deruxtecan plus pertuzumab …

    Source: Healio News - Neutral
  • Published on Jun 19, 2025

    FDA Approves Lenacapavir for Prevention of HIV

    The FDA has approved lenacapavir (Yeztugo) as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV in adult and adolescent patients weighing at least 35kg, Gilead Sciences announced in a release.1 The decision makes the therapy the …

    Source: Drug Topics - Neutral
  • Published on Jun 19, 2025

    STAT+: Gilead won U.S. approval for HIV prevention shot, but when will low-income countries gain sufficient access?

    Now that Gilead Sciences has won U.S. regulatory approval for its groundbreaking HIV prevention drug, the company has another hurdle to clear — ensuring the medicine can be accessed in low-income countries where the disease remains a stubborn problem. As …

    Source: STAT - Massachusetts - Neutral
  • Published on Jun 19, 2025

    MBTA to borrow $939 million as deficit looms

    HEALTH CARE The world’s only twice-a-year shot to prevent HIV could stop transmission — if people can get it The United States has approved the world’s only twice-a-year shot to prevent HIV, the first step in an anticipated global rollout that could …

    Source: The Boston Globe - Massachusetts - Neutral
  • Published on Jun 19, 2025

    FDA approves long-lasting HIV-prevention drug

    June 18 (UPI) -- The Food and Drug Administration has approved a new drug that could prevent HIV infections with just two shots every year and possibly eradicate the disease. The drug's scientific name is lenacapavir and it will be marketed as Yeztugo, …

    Source: United Press International (UPI) - Neutral
  • Published on Jun 18, 2025

    Gilead's twice-yearly PrEP drug is cleared by FDA

    Gilead Sciences has cemented its dominant position in the market for HIV pre-exposure prophylaxis (PrEP) after claiming FDA approval for a drug, Yeztugo, that provides protection with an injection given every six months. The decision has been long …

    Source: pharmaphorum - Neutral
  • Published on Jun 18, 2025

    'Milestone moment': US approves twice-yearly HIV prevention jab Yeztugo

    Key Points The US FDA has approved Gilead's twice-yearly HIV prevention jab, branded as Yeztugo. The lenacapavir injection proved nearly 100 per cent effective in large-scale clinical trials. Gilead is planning a rapid launch in the US and a wider …

    Source: SBS - Public Broadcaster
  • Published on Jun 18, 2025

    FDA approves twice-yearly shot of Gilead drug for HIV prevention

    The Food and Drug Administration has approved a new way to prevent HIV, clearing a Gilead Sciences drug that requires only two injections a year to protect against infections.  The treatment, known scientifically as lenacapavir and to be sold as Yeztugo, …

    Source: BioPharma Dive - Pending
  • Published on Jun 18, 2025

    Gilead's HIV Drug Is 99.9% Effective. Could Politics Derail It?

    Gilead Sciences (GILD) won Food and Drug Administration approval Wednesday for a highly-effective drug to prevent HIV infection. The twice-yearly shot, formerly called lenacapavir, will sell under the brand name Yeztugo. In one test, none of the more than …

    Source: Investor's Business Daily - Neutral
  • Published on Jun 18, 2025

    FDA Approves “Breakthrough” HIV Drug

    Ulrich Baumgarten/Getty Get your news from a source that’s not owned and controlled by oligarchs. Sign up for the free Mother Jones Daily. On Wednesday, the Food and Drug Administration approved a highly effective, injectable drug to help prevent the …

    Source: Mother Jones - Left-wing
  • Published on Jun 18, 2025

    Gilead's twice-yearly HIV prevention injection gets FDA approval

    00:00 Speaker A What's a big milestone for Gilead Sciences today. The Biotech Giant securing FDA approval for its latest HIV treatment. It's a significant step forward for that company and patients. Gilead also seeing a boost on that news. Our …

    Source: Yahoo Finance - Center-left
  • Published on Jun 18, 2025

    AP Business SummaryBrief at 6:45 p.m. EDT

    NTSB urges quick fix on Boeing plane engines to prevent smoke from filling cabin after a bird strike Safety experts recommend that the engines on Boeing’s troubled 737 Max airplanes be modified quickly to prevent smoke from filling the cockpit or cabin …

    Source: Voice of Alexandria - Minnesota - Pending
  • Published on Jun 18, 2025

    The world's only twice-a-year shot to prevent HIV could stop transmission -- if people can get it

    WASHINGTON — (AP) — The U.S. has approved the world's only twice-a-year shot to prevent HIV, the first step in an anticipated global rollout that could protect millions – although it's unclear how many in the U.S. and abroad will get access to the …

    Source: WJAX - Florida - Neutral
  • Published on Jun 18, 2025

    FDA Approves Twice-Yearly Lenacapavir for HIV Preexposure Prophylaxis

    The FDA has approved lenacapavir (Yeztugo; Gilead Sciences), a twice-yearly injectable HIV-1 capsid inhibitor, for the prevention of HIV as preexposure prophylaxis (PrEP), according to reports from NBC News, USA Today, and CNBC and a news release from …

    Source: Pharmacy Times - Neutral
  • Published on Jun 18, 2025

    HIV prevention drug hailed as a 'breakthrough' gets FDA approval

    A drug with the potential to drastically curb the HIV epidemic just cleared its first regulatory hurdle. On Wednesday, the Food and Drug Administration approved lenacapavir for the prevention of HIV. Clinical trial data from last year suggest just two …

    Source: WPRL - Mississippi - Public Broadcaster
  • Published on Jun 18, 2025

    FDA Approves Gilead’s Twice-Yearly Injectable Lenacapavir (Yeztugo) for HIV Prevention

    Gilead Sciences, Inc announced today that the US Food and Drug Administration (FDA) has granted approval for yeztugo, the company’s first-in-class, long-acting HIV-1 capsid inhibitor, for use as a twice-yearly pre-exposure prophylaxis (PrEP) to prevent HIV …

    Source: ContagionLive - Neutral

10 days 06:08:26

Featured Releases

Got News to Share? · Submit · See All
Got news to share? Submit it now.
Load more pharmaceuticals news or search news using your own keywords. There are 824,487,399 articles in our news database.

Online News Monitoring Made Simple

Established in 1995, EIN Newsdesk helps millions of users track breaking news across thousands of trusted websites. Users may set up custom email newsletters and RSS feeds or search among thousands of preset news sections. As a member, you may also submit your own news using the EIN Presswire distribution service. Membership is free and we do not sell or lease any information about you. Press release distribution, dedicated APIs, and custom services generate the revenue that allow us to offer you free basic access.

News by Country & by Industry

Worldwide News Coverage

Track news across more than 5,000 sources by country or industry or search our real-time news index.

Pharmaceutical Industry News by Country >
Pharmaceutical Industry News by U.S. State >
Pharmaceutical Industry News Topics >
Online News Publications >
World News Report >

News Alerts & News Feeds

Custom News Monitoring

News page results can be outputted as RSS or received daily by email. You may also use our NewsPlugin for WordPress.

Create Email Newsletter >
Create RSS Feed >
NewsPlugin for WordPress >

Submit News

PR Distribution Service

Our EIN Presswire's distribution footprint reaches millions. You can upload news which is re-published through EIN Newsdesk, fed into Twitter and Facebook, and onto partner sites, Google News, Bing News, etc.

EIN Presswire >
Events >

World Media Directory

News Media Guide

This is a listing of the world’s TV stations, radio stations, newspapers, and blogs. Last update: 06/17/2025

World Media Directory >

Healthcare & Pharmaceuticals Industry Press Releases

Got News to Share? · Submit · See All
Got news to share? Submit it now.

Healthcare & Pharmaceuticals Events

See All

No event was found.

Become a Member - Join Today!
Join thousands of professionals. Stay current. Stay competitive.
  • Track news from thousands of sources
  • Submit news sources for inclusion in our news tracking algorithm
  • Build your own customized email newsletters
  • Use of our RSS Feeds
  • Includes a complimentary EIN Presswire account plus 1-free release
  • Uncluttered & advertising free news pages

Pharmaceutical Industry Today by EIN Newsdesk & EIN Presswire (a press release distribution service)

Follow us on Facebook and connect with us on LinkedIn

Newsmatics Inc., 1025 Connecticut Avenue NW, Suite 1000, Washington, DC 20036 · Contact · About

© 1995-2025 Newsmatics Inc., a publisher of EIN News · All Rights Reserved · Privacy Policy · User Agreement